Chia Tai Tianqing：Symproic®Naldemedinehas been formally accepted for review.

Naldemedine, developed by Shionogi and commercialized in China by Chia Tai Tianqing, has been officially approved for marketing by the NMPA (acceptance number: JXHS2500060). It is specifically indicated for the treatment of opioid-induced constipation (OIC), filling a gap in precise clinical treatment in China.

Naldemedine is the world’s first approved oral selective peripheral mu-opioid receptor antagonist, with a precise and unique mechanism of action. The drug specifically blocks the binding of opioids to mu receptors in the gut, fundamentally reversing the pathological effects of opioids that inhibit gastrointestinal motility and reduce intestinal fluid secretion. It rapidly restores normal physiological rhythm of the intestine, efficiently improving OIC symptoms, while having no impact on the central analgesic effects of opioids, balancing both efficacy and safety.

This new drug has been approved for marketing in multiple countries and regions, including the United States, the European Union, Japan, and Hong Kong (China). Its domestic launch process has been steadily advancing. In 2022, it was introduced to the Hainan Lecheng Medical Pilot Zone as a clinically urgently needed drug. In April 2026, leveraging Guangdong’s “Hong Kong-Macao Drug and Medical Device Connect” policy, it was first made available at designated medical institutions in the Guangdong-Hong Kong-Macao Greater Bay Area. Now, with formal approval from the NMPA, it has achieved compliant nationwide marketing in China.

Buy Symproic®（Naldemedine） online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.